Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

zanolimumab

Known as: Anti-CD4 Monoclonal Antibody HuMax, HuMax-CD4 
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
BackgroundHuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2017
2017
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
The complex signaling networks of the tumor microenvironment that facilitate tumor growth and progression toward metastatic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
Primary cutaneous T-cell lymphomas (CTCL) are rare malignancies characterized by clonal T-cell infiltrates (Kim et al, 2005… Expand
  • figure 1
Is this relevant?
Review
2011
Review
2011
New antibody drug treatments for lymphoma.
INTRODUCTION The advent of anti-CD20 monoclonal antibody (mAb) rituximab heralded a new era in the treatment of non-Hodgkin's… Expand
Is this relevant?
2010
2010
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was… Expand
Is this relevant?
Review
2008
Review
2008
Novel human antibody therapeutics: The age of the Umabs
Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2007
2007
Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4 + T-Cell Lymphoma.
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are… Expand
Is this relevant?
2006
2006
In situ depletion of CD4+ T cells in human skin by Zanolimumab
CD4+ T cells, in activated or malignant form, are involved in a number of diseases including inflammatory skin diseases such as… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
OBJECTIVE Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE